Murat Berkkanoglu1, Kevin Coetzee2, Hasan Bulut2, Kemal Ozgur2. 1. Antalya IVF, Halide Edip Cd. No: 7, Kanal Mh, Antalya, 07080, Turkey. mberkkan@hotmail.com. 2. Antalya IVF, Halide Edip Cd. No: 7, Kanal Mh, Antalya, 07080, Turkey.
Abstract
PURPOSE: In this retrospective cohort study, we investigated the best embryo transfer strategy in ICSI cycles with ≤4 oocytes collected at oocyte retrieval. METHODS: Women who underwent antagonist co-treatment COS for ICSI treatment between January 2010 and December 2015 at a private ART clinic (N = 2263). Eight hundred seventy-nine women (group 1) had ≤4 oocytes collected at oocyte retrieval, of whom 645 (group A) had cleavage stage embryo transfer (ET), and 234 (group B) had blastocyst ET. One thousand three hundred eighty-four women (group 2) had 10-15 oocytes collected at oocyte retrieval, of whom 676 (group C) had cleavage stage ET, and 708 women (group D) had blastocyst ET. Blastocyst vitrification was performed using the Cryotop method and FET using artificial cycles. RESULTS: In group 1, the cancellation rate was significantly lower in group A (25.2 vs 38 %). The pregnancy rate (PR), clinical PR, implantation rate (IR), and live birth rate (LBR) per ET and per oocyte retrieval were all lower in group A. The clinical PR, IR, and LBR per ET of vitrified-warmed blastocyst ET were significantly the highest. In group 2, the cycle cancellation rate was significantly lower in group C (3.5 vs 13.4 %). The PR, clinical PR, and IR per ET and per oocyte retrieval were all lower in group C. The LBR per ET was significantly lower, but the LBR per oocyte retrieval was not significantly lower in group C. Again, the PR, clinical PR, and IR per ET of vitrified-warmed blastocyst ET were significantly the highest. CONCLUSIONS: Day 5 ET strategy has been reserved for normal or high responders. The improved pregnancy outcomes from blastocyst culture and cryopreservation may challenge ART to extend this benefit to poor responders.
PURPOSE: In this retrospective cohort study, we investigated the best embryo transfer strategy in ICSI cycles with ≤4 oocytes collected at oocyte retrieval. METHODS:Women who underwent antagonist co-treatment COS for ICSI treatment between January 2010 and December 2015 at a private ART clinic (N = 2263). Eight hundred seventy-nine women (group 1) had ≤4 oocytes collected at oocyte retrieval, of whom 645 (group A) had cleavage stage embryo transfer (ET), and 234 (group B) had blastocyst ET. One thousand three hundred eighty-four women (group 2) had 10-15 oocytes collected at oocyte retrieval, of whom 676 (group C) had cleavage stage ET, and 708 women (group D) had blastocyst ET. Blastocyst vitrification was performed using the Cryotop method and FET using artificial cycles. RESULTS: In group 1, the cancellation rate was significantly lower in group A (25.2 vs 38 %). The pregnancy rate (PR), clinical PR, implantation rate (IR), and live birth rate (LBR) per ET and per oocyte retrieval were all lower in group A. The clinical PR, IR, and LBR per ET of vitrified-warmed blastocyst ET were significantly the highest. In group 2, the cycle cancellation rate was significantly lower in group C (3.5 vs 13.4 %). The PR, clinical PR, and IR per ET and per oocyte retrieval were all lower in group C. The LBR per ET was significantly lower, but the LBR per oocyte retrieval was not significantly lower in group C. Again, the PR, clinical PR, and IR per ET of vitrified-warmed blastocyst ET were significantly the highest. CONCLUSIONS: Day 5 ET strategy has been reserved for normal or high responders. The improved pregnancy outcomes from blastocyst culture and cryopreservation may challenge ART to extend this benefit to poor responders.
Authors: Marie D Werner; Mark P Leondires; William B Schoolcraft; Brad T Miller; Alan B Copperman; Edwin D Robins; Francisco Arredondo; Timothy N Hickman; Jacqueline Gutmann; Wendy J Schillings; Brynn Levy; Deanne Taylor; Nathan R Treff; Richard T Scott Journal: Fertil Steril Date: 2014-10-22 Impact factor: 7.329
Authors: Peter Humaidan; E G Papanikolaou; D Kyrou; B Alsbjerg; N P Polyzos; P Devroey; Human M Fatemi Journal: Reprod Biomed Online Date: 2011-11-09 Impact factor: 3.828
Authors: Evangelos G Papanikolaou; Efstratios M Kolibianakis; Herman Tournaye; Christos A Venetis; Human Fatemi; Basil Tarlatzis; Paul Devroey Journal: Hum Reprod Date: 2007-10-26 Impact factor: 6.918
Authors: Jinpeng Rao; Feng Qiu; Shen Tian; Ya Yu; Ying Zhang; Zheng Gu; Yiting Cai; Fan Jin; Min Jin Journal: J Int Med Res Date: 2021-12 Impact factor: 1.671